Pelthos Therapeutics Inc. Common Stock PTHS 深 滬
等待開盤 07-18 09:30:00 美东时间
22.13
+1.955
+9.69%
華盛通- 最 高22.695
- 今 開21.13
- 成交量 3.07万股
- 最 低 19.895
- 昨 收 20.175
- 總市值 1.96亿
- 52周最高 54.29
- 市盈率 靜 --
- 換手率 0.35%
- 52周最低 4.50
- 委 比 0.00%
- 總股本 883.51万
- 歷史最高 60.00
- 量 比 0.15
- 振 幅 13.88%
- 歷史最低 4.50
- 每 手 1
- 風險率 5.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | 稀土矿商MP飙升逾50%！五角大楼将成其最大股东；KLG隔夜涨超30%
稀土矿商MP飙升逾50%！五角大楼将成其最大股东；KLG隔夜涨超30%，获费列罗31亿美元收购>>
07-11 18:21
Ligand Pharm's Partner Pelthos Therapeutics Commercially Launches ZELSUVMI Topical Gel 10.3%, FDA-Approved At-Home Treatment For Molluscum Contagiosum
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE:PTHS) has commercially launched ZELSUVMI™ (berdazimer) topical gel 10.3%, the first and only
07-10 20:09
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™
Ligand Pharmaceuticals announced that its partner Pelthos Therapeutics has launched ZELSUVMI™, the first FDA-approved at-home treatment for molluscum contagiosum, earning Ligand a $5 million milestone payment. Ligand now owns 56% of Pelthos post-merger and is entitled to a 13% royalty on ZELSUVMI sales and up to an additional $5 million in milestones. ZELSUVMI, developed using Ligand's NITRICIL™ technology, is the first topical prescription medic...
07-10 12:00
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Mustang Bio (NASDAQ:MBIO) stock increased by 217.6% to $3.78 during Mo...
07-08 01:06
Pelthos Therapeutics Completes Merger With Channel Therapeutics, Closes $50.1M Private Placement, And Prepares For July 2025 ZELSUVMI Launch
The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity
07-02 19:14
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics
Ligand Pharmaceuticals completed its merger with Channel Therapeutics to form Pelthos Therapeutics, which will begin trading on the NYSE American under the ticker "PTHS" on July 2, 2025. Pelthos plans to launch ZELSUVMI, a novel topical gel for treating Molluscum contagiosum infections, later this summer. Ligand invested $18 million in the combined company and will receive a 13% royalty on ZELSUVMI's worldwide sales. The merger also included a $5...
07-02 11:00
Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
Pelthos Therapeutics Inc., formed through the merger of Channel Therapeutics and Ligand’s LNHC, will debut on the NYSE American exchange under ticker "PTHS" on July 2, 2025. The company plans to launch ZELSUVMI™, a novel topical gel for molluscum contagiosum, in July 2025. Concurrently, Pelthos secured $50.1 million in a private equity placement, including repayment of $18.8 million in prior bridge financing. The company aims to leverage its nitr...
07-02 11:00
